While Beam Therapeutics Inc has underperformed by -1.86%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BEAM fell by -8.89%, with highs and lows ranging from $49.50 to $20.84, whereas the simple moving average fell by -3.51% in the last 200 days.
On November 06, 2024, Leerink Partners Upgraded Beam Therapeutics Inc (NASDAQ: BEAM) to Outperform. A report published by Scotiabank on October 16, 2024, Initiated its previous ‘Sector Outperform’ rating for BEAM. H.C. Wainwright also rated BEAM shares as ‘Buy’, setting a target price of $80 on the company’s shares in an initiating report dated July 23, 2024. JP Morgan January 29, 2024d the rating to Overweight on January 29, 2024, and set its price target from $38 to $40. BofA Securities December 15, 2023d its ‘Buy’ rating to ‘Neutral’ for BEAM, as published in its report on December 15, 2023. Jefferies’s report from December 08, 2023 suggests a price prediction of $30 for BEAM shares, giving the stock a ‘Hold’ rating. Leerink Partners also rated the stock as ‘Market Perform’.
Analysis of Beam Therapeutics Inc (BEAM)
Further, the quarter-over-quarter decrease in sales is -17.01%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Beam Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -18.29% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.69, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and BEAM is recording an average volume of 1.12M. On a monthly basis, the volatility of the stock is set at 7.00%, whereas on a weekly basis, it is put at 5.62%, with a loss of -13.59% over the past seven days. Furthermore, long-term investors anticipate a median target price of $49.20, showing growth from the present price of $24.80, which can serve as yet another indication of whether BEAM is worth investing in or should be passed over.
How Do You Analyze Beam Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.25%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.94% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BEAM shares are owned by institutional investors to the tune of 81.94% at present.
